Innova Captab

Why is Innova Captab Ltd falling/rising?

As of 06-Aug, Innova Captab Ltd's stock price is rising to 958.90, driven by strong investor interest and positive financial indicators, including a low Debt to EBITDA ratio and high institutional holdings. The stock has outperformed its sector and is trading above key moving averages, suggesting continued momentum.

As of 06-Aug, Innova Captab Ltd's stock price is rising, currently at 958.90, reflecting an increase of 15.3 points or 1.62%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 1.74% today and has shown consecutive gains over the last two days, accumulating a total return of 1.94% in that period. Additionally, the stock reached an intraday high of Rs 965.35, indicating strong buying interest.<BR><BR>Investor participation has also increased, with a delivery volume of 13.17k on 05 Aug, which is a slight rise of 0.05% compared to the 5-day average delivery volume. This suggests that more investors are willing to hold onto the stock, contributing to its price increase. Furthermore, the stock is trading above its 5-day, 50-day, 100-day, and 200-day moving averages, which is typically a positive indicator of momentum.<BR><BR>The company's financial health supports this rise, as it has a low Debt to EBITDA ratio of 1.44 times, indicating a strong ability to service its debt. With a return on capital employed (ROCE) of 13.9 and an attractive valuation compared to its peers, the stock is seen as a good investment opportunity. High institutional holdings at 20.26% also suggest confidence from larger investors, who often have more resources to analyze company fundamentals.<BR><BR>Overall, these factors combined contribute to the rising stock price of Innova Captab Ltd.

Which are the latest news on Innova Captab?

Should I buy, sell or hold Innova Captab Ltd?

What does Innova Captab do?

Innova Captab Ltd is a Small Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 448 Cr and a net profit of 38 Cr for the quarter ending March 2026. Key metrics include a P/E of 37.00, a dividend yield of 0.22%, and a market cap of INR 5,235 Cr.

Overview:<BR>Innova Captab Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Small Cap company.<BR><BR>History:<BR>Innova Captab Ltd was incorporated in 2005 under the name 'Harun Health Care Private Limited' and later changed its name in 2010. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 448 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 38 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 5,235 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 37.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.22% <BR>Debt-Equity: 0.27 <BR>Return on Equity: 12.92% <BR>Price to Book: 4.88 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Innova Captab?

As of 10th June, Innova Captab Ltd has a market capitalization of 5,235.00 Cr, with net sales of 1,630.01 Cr and a net profit of 140.92 Cr for the latest four quarters. The company has shareholder's funds of 1,090.79 Cr and total assets of 1,835.96 Cr as of March 2026.

As of 10th June, Innova Captab Ltd has a market capitalization of 5,235.00 Cr, categorizing it as a Small Cap company.<BR><BR>For the latest four quarters, Innova Captab reported net sales of 1,630.01 Cr and a net profit of 140.92 Cr.<BR><BR>As of March 2026, the company has shareholder's funds amounting to 1,090.79 Cr and total assets of 1,835.96 Cr.

Who are the peers of the Innova Captab?

Innova Captab's peers include Supriya Lifesci, Sanofi India, SPARC, FDC, Aarti Pharma, Senores Pharma, Bliss GVS Pharma, Orchid Pharma, and Guj. Themis Bio. Management risk varies from excellent to below average, with Senores Pharma showing the highest 1-year return at 117.05% and Innova Captab at 7.53%.

Peers: The peers of Innova Captab are Supriya Lifesci., Sanofi India, SPARC, FDC, Aarti Pharma, Senores Pharma., Bliss GVS Pharma, Orchid Pharma, Guj. Themis Bio.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanofi India and Guj. Themis Bio., while Good management risk is found at Innova Captab and Supriya Lifesci. Average management risk is present at SPARC, FDC, Aarti Pharma, Senores Pharma., and Bliss GVS Pharma, and the rest have Below Average management risk. Growth is Excellent at Senores Pharma. and SPARC, while Below Average growth is seen at Innova Captab, Sanofi India, FDC, Aarti Pharma, Bliss GVS Pharma, Orchid Pharma, and the rest. Excellent capital structure is noted at Supriya Lifesci., Sanofi India, FDC, Aarti Pharma, Bliss GVS Pharma, and Guj. Themis Bio., while Average capital structure is found at SPARC, and Below Average at Orchid Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Senores Pharma. at 117.05%, while the lowest is Sanofi India at -48.68%. Innova Captab's 1-year return is 7.53%, which is significantly higher than Sanofi India but lower than Senores Pharma. Additionally, the six-month returns for Sanofi India and Guj. Themis Bio. are negative.

Are Innova Captab Ltd latest results good or bad?

Innova Captab Ltd's latest results show strong year-on-year growth in revenue (up 42.28%) and net profit (up 28.78%), but sequential declines in net profit (down 9.66%) and margins raise concerns about profitability challenges. Overall, the results are mixed, indicating both positive growth and emerging issues.

Innova Captab Ltd's latest results present a mixed picture. For the fourth quarter of FY26, the company reported a net profit of ₹38.08 crore, which reflects a decline of 9.66% compared to the previous quarter. However, this figure shows a significant year-on-year increase of 28.78%. <BR><BR>Revenue for the same quarter was ₹447.80 crore, down slightly by 0.55% from the previous quarter but up by an impressive 42.28% year-on-year. Despite this strong revenue growth, the company faced challenges with profitability, as both operating margins and profit after tax (PAT) margins decreased sequentially. The operating margin fell to 14.54%, down from 15.41%, and the PAT margin declined to 8.50% from 9.36%.<BR><BR>Overall, while the year-on-year growth in revenue and profit is encouraging, the sequential declines in both net profit and margins indicate emerging challenges that could raise concerns among investors. The company's ability to manage costs and maintain profitability will be crucial moving forward.

When is the next results date for Innova Captab Ltd?

The next results date for Innova Captab Ltd is 07 May 2026.

The next results date for Innova Captab Ltd is scheduled for 07 May 2026.

Is Innova Captab technically bullish or bearish?

As of December 1, 2025, the market trend is mildly bearish due to bearish momentum from the MACD and KST, despite some bullish strength in the RSI, indicating a cautious approach is warranted.

As of 1 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish momentum, while the daily moving averages also reflect a bearish outlook. The weekly RSI shows bullish strength, but this is countered by the bearish signals from the Bollinger Bands. Dow Theory indicates a mildly bullish trend on the weekly chart, but overall, the mixed signals suggest a cautious approach. The stock has underperformed significantly against the Sensex over multiple time frames, further supporting the bearish sentiment.

How has been the historical performance of Innova Captab?

Innova Captab has shown consistent growth over the past three years, with net sales rising from 926.38 Cr in Mar'23 to 1,243.68 Cr in Mar'25, and profit after tax increasing from 67.95 Cr to 128.26 Cr. The company's total assets and liabilities also expanded significantly during this period.

Answer:<BR>The historical performance of Innova Captab shows a consistent growth trajectory in key financial metrics over the past three years.<BR><BR>Breakdown:<BR>Innova Captab's net sales increased from 926.38 Cr in Mar'23 to 1,243.68 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed suit, reaching 1,243.68 Cr in Mar'25, up from 926.38 Cr in Mar'23. The company's total expenditure also rose, from 812.73 Cr in Mar'23 to 1,057.52 Cr in Mar'25, driven by higher raw material costs and employee expenses. Operating profit (PBDIT) improved significantly, climbing from 122.85 Cr in Mar'23 to 198.21 Cr in Mar'25, while profit before tax increased from 91.80 Cr to 171.02 Cr in the same period. Consequently, profit after tax surged from 67.95 Cr in Mar'23 to 128.26 Cr in Mar'25, resulting in an earnings per share (EPS) growth from 14.16 to 22.41. The company's total assets expanded from 704.29 Cr in Mar'23 to 1,568.17 Cr in Mar'25, with total liabilities also increasing from 704.29 Cr to 1,568.17 Cr. Cash flow from operating activities showed variability but ended at 63.00 Cr in Mar'25, while cash flow from financing activities was positive at 91.00 Cr. Overall, Innova Captab has demonstrated robust growth in revenue and profitability, alongside a significant increase in assets and liabilities over the past three years.

Is Innova Captab overvalued or undervalued?

As of November 6, 2025, Innova Captab is considered undervalued with an attractive valuation grade, featuring a PE ratio of 35.54, an EV to EBITDA of 24.91, and a PEG ratio of 0.99, indicating better growth potential compared to peers despite recent underperformance against the Sensex.

As of 6 November 2025, Innova Captab has moved from a fair to attractive valuation grade, indicating a more favorable outlook. The company is currently considered undervalued. Key ratios include a PE ratio of 35.54, an EV to EBITDA of 24.91, and a PEG ratio of 0.99, which suggests that the stock is priced reasonably relative to its growth potential.<BR><BR>In comparison to its peers, Innova Captab's PE ratio is higher than Sun Pharma's 35.02 but lower than Divi's Lab's significantly high 79.09, indicating a competitive position within the industry. Additionally, while Cipla has a more attractive PE of 22.27, Innova Captab's PEG ratio of 0.99 suggests it offers better growth at its current price. Despite recent underperformance against the Sensex, with a year-to-date return of -26.98% compared to the Sensex's 6.62%, the valuation metrics support a bullish outlook for the stock moving forward.

Who are the top shareholders of the Innova Captab?

The top shareholders of Innova Captab include promoter Manoj Lohariwala with 29.07%, public shareholder Gian Parkash Aggarwal with 21.65%, individual investors with 27.62%, mutual funds holding 10.75%, and foreign institutional investors at 0.34%.

The top shareholders of Innova Captab include the promoters, who hold the majority of the shares. The promoter with the highest holding is Manoj Lohariwala, with a stake of 29.07%. Additionally, Gian Parkash Aggarwal is the highest public shareholder, holding 21.65%. Individual investors collectively own 27.62% of the company. Mutual funds have a presence through 9 schemes, holding 10.75%, while foreign institutional investors (FIIs) hold a smaller portion at 0.34%.

Has Innova Captab declared dividend?

No Dividend History Available